244 related articles for article (PubMed ID: 23121406)
21. A novel mechanism of action of chemically modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production.
Patel RN; Attur MG; Dave MN; Patel IV; Stuchin SA; Abramson SB; Amin AR
J Immunol; 1999 Sep; 163(6):3459-67. PubMed ID: 10477618
[TBL] [Abstract][Full Text] [Related]
22. Unraveling the molecular structure of the catalytic domain of matrix metalloproteinase-2 in complex with a triple-helical peptide by means of molecular dynamics simulations.
Díaz N; Suárez D; Valdés H
Biochemistry; 2013 Nov; 52(47):8556-69. PubMed ID: 24164447
[TBL] [Abstract][Full Text] [Related]
23. Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.
Gu Y; Lee HM; Simon SR; Golub LM
Pharmacol Res; 2011 Dec; 64(6):595-601. PubMed ID: 21651982
[TBL] [Abstract][Full Text] [Related]
24. Molecular dynamics simulations of the active matrix metalloproteinase-2: positioning of the N-terminal fragment and binding of a small peptide substrate.
Díaz N; Suárez D
Proteins; 2008 Jul; 72(1):50-61. PubMed ID: 18186480
[TBL] [Abstract][Full Text] [Related]
25. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
Singh T; Adekoya OA; Jayaram B
Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
[TBL] [Abstract][Full Text] [Related]
26. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
[TBL] [Abstract][Full Text] [Related]
27. Alternative interdomain configurations of the full-length MMP-2 enzyme explored by molecular dynamics simulations.
Díaz N; Suárez D
J Phys Chem B; 2012 Mar; 116(9):2677-86. PubMed ID: 22324833
[TBL] [Abstract][Full Text] [Related]
28. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.
Lokeshwar BL
Pharmacol Res; 2011 Feb; 63(2):146-50. PubMed ID: 21093590
[TBL] [Abstract][Full Text] [Related]
29. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
30. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.
Laghezza A; Luisi G; Caradonna A; Di Pizio A; Piemontese L; Loiodice F; Agamennone M; Tortorella P
Bioorg Med Chem; 2020 Feb; 28(3):115257. PubMed ID: 31874775
[TBL] [Abstract][Full Text] [Related]
31. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity.
Ryan ME; Usman A; Ramamurthy NS; Golub LM; Greenwald RA
Curr Med Chem; 2001 Feb; 8(3):305-16. PubMed ID: 11172685
[TBL] [Abstract][Full Text] [Related]
32. A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.
Rizzo RC; Toba S; Kuntz ID
J Med Chem; 2004 Jun; 47(12):3065-74. PubMed ID: 15163188
[TBL] [Abstract][Full Text] [Related]
33. Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes.
Terp GE; Christensen IT; Jørgensen FS
J Biomol Struct Dyn; 2000 Jun; 17(6):933-46. PubMed ID: 10949161
[TBL] [Abstract][Full Text] [Related]
34. Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies.
Ammazzalorso A; De Filippis B; Campestre C; Laghezza A; Marrone A; Amoroso R; Tortorella P; Agamennone M
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27782083
[TBL] [Abstract][Full Text] [Related]
35. A study on quantitative structure-activity relationship and molecular docking of metalloproteinase inhibitors based on L-tyrosine scaffold.
Abbasi M; Ramezani F; Elyasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2015 Apr; 23(1):29. PubMed ID: 25925871
[TBL] [Abstract][Full Text] [Related]
36. Computational Approaches to Matrix Metalloprotease Drug Design.
Singh T; Jayaram B; Adekoya OA
Methods Mol Biol; 2017; 1579():273-285. PubMed ID: 28299743
[TBL] [Abstract][Full Text] [Related]
37. Grafting of functional motifs onto protein scaffolds identified by PDB screening--an efficient route to design optimizable protein binders.
Tlatli R; Nozach H; Collet G; Beau F; Vera L; Stura E; Dive V; Cuniasse P
FEBS J; 2013 Jan; 280(1):139-59. PubMed ID: 23121732
[TBL] [Abstract][Full Text] [Related]
38. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.
Islam MM; Franco CD; Courtman DW; Bendeck MP
Am J Pathol; 2003 Oct; 163(4):1557-66. PubMed ID: 14507662
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis.
Maitra SR; Bhaduri S; Valane PD; Tervahartiala T; Sorsa T; Ramamurthy N
Shock; 2003 Sep; 20(3):280-5. PubMed ID: 12923502
[TBL] [Abstract][Full Text] [Related]
40. N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.
Campestre C; Agamennone M; Tortorella P; Preziuso S; Biasone A; Gavuzzo E; Pochetti G; Mazza F; Hiller O; Tschesche H; Consalvi V; Gallina C
Bioorg Med Chem Lett; 2006 Jan; 16(1):20-4. PubMed ID: 16242329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
